363 related articles for article (PubMed ID: 17283142)
1. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
2. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
Finger EC; Turley RS; Dong M; How T; Fields TA; Blobe GC
Carcinogenesis; 2008 Mar; 29(3):528-35. PubMed ID: 18174241
[TBL] [Abstract][Full Text] [Related]
3. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
[TBL] [Abstract][Full Text] [Related]
4. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
5. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
[TBL] [Abstract][Full Text] [Related]
6. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
7. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
8. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
[TBL] [Abstract][Full Text] [Related]
9. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Ko Y; Banerji SS; Liu Y; Li W; Liang J; Soule HD; Pauley RJ; Willson JK; Zborowska E; Brattain MG
J Cell Physiol; 1998 Aug; 176(2):424-34. PubMed ID: 9648930
[TBL] [Abstract][Full Text] [Related]
10. TGFBR3 loss and consequences in prostate cancer.
Sharifi N; Hurt EM; Kawasaki BT; Farrar WL
Prostate; 2007 Feb; 67(3):301-11. PubMed ID: 17192875
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of type III TGF-β receptor aggravates lung fibrotic process.
Ahn JY; Park S; Yun YS; Song JY
Biomed Pharmacother; 2010 Sep; 64(7):472-6. PubMed ID: 20359848
[TBL] [Abstract][Full Text] [Related]
13. TGF beta (transforming growth factor beta) receptor type III directs clathrin-mediated endocytosis of TGF beta receptor types I and II.
McLean S; Di Guglielmo GM
Biochem J; 2010 Jul; 429(1):137-45. PubMed ID: 20406198
[TBL] [Abstract][Full Text] [Related]
14. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
15. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
17. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
18. Calpain-2 as a target for limiting prostate cancer invasion.
Mamoune A; Luo JH; Lauffenburger DA; Wells A
Cancer Res; 2003 Aug; 63(15):4632-40. PubMed ID: 12907643
[TBL] [Abstract][Full Text] [Related]
19. EphB4 expression and biological significance in prostate cancer.
Xia G; Kumar SR; Masood R; Zhu S; Reddy R; Krasnoperov V; Quinn DI; Henshall SM; Sutherland RL; Pinski JK; Daneshmand S; Buscarini M; Stein JP; Zhong C; Broek D; Roy-Burman P; Gill PS
Cancer Res; 2005 Jun; 65(11):4623-32. PubMed ID: 15930280
[TBL] [Abstract][Full Text] [Related]
20. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
